AVNT vs CBT: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
AVNT and CBT are similarly sized, but CBT trades noticeably cheaper on forward earnings (10.86x vs 12.57x): the market is paying up for AVNT's profile and pricing CBT more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
AVNT vs CBT: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AVNT | CBT | What it tells you |
|---|---|---|---|
| Market cap | $4.06B | $3.93B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 12.57 | 10.86 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 23.91 | 21.33 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.25 | 0.82 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 87% of range | 49% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.66 | 2.45 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: CBT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how AVNT and CBT affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AVNT and CBT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AVNT and CBT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Avient Corporation (AVNT) do?
Avient Corporation makes formulated materials rather than base chemicals. It buys polymer resin and pigment and sells engineered recipes: masterbatch colorants, functional additives, specialty inks, thermoplastic elastomers, composites and the Dyneema ultra-high-molecular-weight polyethylene fiber line acquired from DSM in 2022. Two reporting segments carry the business. Color, Additives and Inks is the larger one at roughly $2.0 billion of 2025 sales, and Specialty Engineered Materials contributed about $1.2 billion. End markets are spread across packaging, consumer goods, healthcare and pharmaceutical devices, building and construction, transportation, wire and cable, and defense. The company employs around 9,000 people and traces its roots to a 1885 founding, having renamed itself from PolyOne in 2020 after selling the commodity distribution and PVC compounding businesses that used to dominate its sales mix.
What does Cabot Corporation (CBT) do?
Cabot Corporation, based in Boston and founded in 1882, makes the black powder that gives tires their strength and wear resistance. Carbon black is mostly sold through its Reinforcement Materials segment to tire makers such as Michelin, Bridgestone and Goodyear, and that segment produced roughly $599 million of the ~$982 million in sales in the June 2026 quarter. The second segment, Performance Chemicals, sells specialty carbons for plastics and coatings, fumed silica and alumina, inkjet colorants and conductive additives for lithium-ion batteries. Cabot sold its activated carbon (Purification Solutions) unit in 2024 to concentrate on these two businesses, and it runs a global network of plants across the Americas, Europe and Asia, including new capacity in Indonesia and a Mexican carbon black producer bought in early 2026.
AVNT vs CBT: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- AVNT drivers: Dyneema capacity for defense; Margin expansion from productivity and pricing.
- CBT drivers: Tire contract pricing and volume recovery; Battery materials and conductive additives.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Organic volume was flat to slightly negative for several quarters before the second quarter of 2026, so the earnings growth on offer still depends heavily on margin gains continuing. For CBT, the biggest risk is that tire pricing keeps resetting lower.
AVNT or CBT: which should you pick?
AVNT vs CBT: the full fundamentals
AVNT. The gap between the trailing P/E near 21 and the forward figure near 11 reflects GAAP earnings that carry restructuring and amortization charges the adjusted figures exclude, so which number an investor uses changes the valuation picture considerably. On adjusted earnings, about 12 times the 2026 guidance midpoint is modest for a specialty formulator, which suggests some discount for the leadership change. Third-quarter results on November 4, 2026 will be the first under the new CEO.
CBT. Figures are approximate and tied to the asOf date; verify live numbers before acting. Fiscal 2026 ended September 30 and full-year results are expected in early November 2026, so trailing figures will shift soon. GAAP earnings look far weaker than adjusted earnings this year because of restructuring and benefit plan charges, including a ~$1.55 per share hit in the June quarter. At roughly 12x adjusted earnings the stock trades near specialty chemical peers' low end, and the average analyst target of ~$89 to $91 sits well above the ~$74 quote, after the shares slid from the mid-$80s in August.
Headline figures (approximate, October 2026): AVNT shows revenue (ttm) ~$3.33 billion (Q2 2026 ~$917 million, +5.8%), q2 2026 adjusted eps ~$0.96 vs ~$0.89 consensus, adjusted eps guidance (2026) ~$3.10 to $3.25 (raised in August, reaffirmed October 9), net income (ttm) ~$170 million (profit margin ~5.1%); CBT shows revenue (ttm) ~$3.6 billion (June 2026 quarter ~$982 million, up ~6% year over year), adjusted eps (fy2026 guidance) ~$6.15 to $6.45 vs $7.25 in FY2025; June quarter ~$1.67, segment ebit (june 2026 quarter) Reinforcement Materials ~$97 million (down ~24%); Performance Chemicals ~$68 million (up ~19%), p/e (adjusted, forward) ~12x on FY2026 guidance at a share price near ~$74.
The bottom line: AVNT vs CBT
AVNT and CBT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AVNT and CBT exposure against your real portfolio. It is not an investment adviser.
Wondering how AVNT or CBT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Avient Corporation with AI
Connect the broker you already use and ask Walnut's AI how AVNT fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between AVNT and CBT?
+
Avient Corporation makes formulated materials rather than base chemicals. Cabot Corporation, based in Boston and founded in 1882, makes the black powder that gives tires their strength and wear resistance. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AVNT or CBT the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AVNT or CBT?
+
On forward P/E (as of November 2026), AVNT trades at 12.57x and CBT at 10.86x, so CBT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AVNT and CBT?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AVNT vs CBT?
+
AVNT: Organic volume was flat to slightly negative for several quarters before the second quarter of 2026, so the earnings growth on offer still depends heavily on margin gains continuing. Roughly $1.88 billion of debt against about $587 million of trailing EBITDA leaves leverage near 2.5 times net of cash, which limits flexibility if end markets soften. Leadership is a new risk: the CEO departure in October 2026 came without a stated reason, and a new chief executive may reset priorities, targets or the portfolio. A large share of sales is outside the United States, so the currency tailwind that flattered early 2026 can reverse. Building and construction, transportation and consumer durables remain cyclical and rate-sensitive, and tariffs and trade policy shifts can move both input costs and customer demand. Defense demand is a policy-driven revenue stream, and the Dyneema capacity expansion assumes budget levels hold through the payback period. CBT: The biggest risk is that tire pricing keeps resetting lower. Western tire makers face heavy competition from low-cost Asian imports, and if they keep losing share or push Cabot harder in the calendar 2027 contract round, Reinforcement Materials earnings could fall again even with higher volumes. Feedstock is another exposure: carbon black is made from heavy oil residues, and while contracts include pass-through mechanisms, sharp oil swings can squeeze margins for a quarter or two. Cabot runs energy-intensive plants that emit significant CO2, so tighter European carbon pricing and US EPA consent-decree obligations raise compliance costs. Battery materials face fierce price competition from Chinese nanotube makers and depend on an electric vehicle market that has slowed in the West. Restructuring brings execution risk, and the Botlek closures still need local approval. A CEO transition adds strategic uncertainty, the former CEO sold about 25% of his stake in August, and Cabot's large operations in China, Indonesia and Latin America expose it to currency moves, tariffs and geopolitical disruption. Finally, analyst consensus sits at Hold, with targets clustered near the current price.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AVNT or CBT; figures are approximate and dated (as of November 2026). Verify current data before investing.